Asian Pacific Journal of Cancer Prevention · 2013 · 27 citations · 26 references
Life SciencesGeneticsImmunologyEpidemiologyGenetic EpidemiologyImmunogeneticsCancer RiskCytokine Gene PolymorphismGenetic Risk AssessmentGenome-wide Association StudiesGenotype-phenotype Association AnalysisInterleukin Gene VariantsCancer Risk AssociationCase-control Study DesignCytokine Promoter PolymorphismDisease Susceptibility AssociationGastric Cancer GeneticsInterleukin-10 Gene VariantsPopulation Genetic AssociationSingle-nucleotide Variants
OBJECTIVES: Interleukin (IL) -10 is a potent cytokine with a dual ability to immunosuppress or immunostimulate. We aimed to explore the association of IL10 promoter polymorphisms with risk of gastric cancer (GC) in a Han population in Southwestern China. METHODS: We enrolled 308 pairs of GC and control subjects from four hospitals and a community between October 2010 and August 2011 in a 1:1 matched case-control design. Demographic information was collected using a designed questionnaire. IL10-592 A>C and IL10-1082 A>G polymorphisms were determined by Sequenom MassARRAY analysis. RESULTS: Patients with GC reported statistically higher proportions of family history of cancer (29.9% versus 10.7%, P<0.01) and alcohol drinking (54.6% versus 43.2%, P<0.01) than did controls. Similar results were observed in comparison between non-cardia GC patients and controls (P<0.01 and P=0.03). Variant genotypes of IL10-592 A>C and IL10-1082 A>G were not associated with overall GC risk (adjusted OR, 0.94, 95% CI, 0.66-1.33; adjusted OR, 1.00, 95% CI, 0.62-1.60). Sub-analysis showed that the IL10-592 AC/CC variant genotype was associated with decreased non-cardia GC risk (adjusted OR, 0.58; 95% CI, 0.36-0.95). No association was found between any of the IL10 haplotypes established from two polymorphisms and risk of non-cardia GC. CONCLUSIONS: In conclusion, our data do not link the two SNPs of IL10-592 and IL10-1082 with overall GC risk. We demonstrate that IL10-592 polymorphism is associated with protective effect against non-cardia GC. Our findings may offer insight into risk associated with the development of GC in this region.
26
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
Farin Kamangar, Graça M. Dores, William F. Anderson · Journal of Clinical Oncology · 2006 · 3.5K citations
AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN‐10 GENE PROMOTER
David M. Turner, Denise Williams, David Sankaran et al. · European Journal of Immunogenetics · 1997 · 1.7K citations
Life Sciences, Genetics, Immunology +14